PROJECT SUMMARY During this funding period the Stanford Cancer Institute (SCI) leveraged its potential as a newly designated comprehensive center. SCI achievements were supported by an experienced and highly-productive SCI administrative team (SCI-A), which broadened its collective contribution to high-impact and collaborative science under the direction of new (2018) SCI Director, Steven Artandi, MD, PhD, and new (2017) Associate Director for Administration and Strategy, Laura Adams, BS. Achievements of SCI-A during this funding period include: 1) seamless management of operations and a fully remote administrative workforce during COVID-19 pandemic; 2) major contributions to a new SCI Strategic Plan which, for the first time, integrates the research, educational and clinical missions of the enterprise (2019); 3) support for the appointment of a Director, Deputy Director, and 9 new Associate Directors, 6 of whom were also new recruitments led by the SCI; 4) transformation of the SCI- A structure; 5) advocacy efforts resulting in a 378% increase ($2.7M to $12.9M) in annual funding from the three principal entities within the parent institution; 6) management of an infusion of new institutional resources provided with Artandi’s recruitment, including additional commitments to faculty recruitment, space, and financial resources; 7) financial and administrative support for the rebuilding of Population Sciences; 8) restructuring and reinvigorating components of the Community Outreach and Engagement (COE) foundation and extensive review of SCI catchment area data; 9) expanding services and creating infrastructure for Cancer Research Training and Education Coordination (CRTEC); 10) impactful integration of the Cancer Clinical Trials Office (CCTO) within the SCI, resulting in expanded organizational prominence to more effectively advance broad CCTO initiatives; 11) assumption of financial oversight for Stanford School of Medicine’s (SOM) contractual relationship with the Parker Institute for Cancer Immunotherapy (PICI) and the new Center for Cancer Cell Therapy (CCCT); 12) assumption of management for the SOM-wide Emerson Collective Cancer Research Awards; 13) strategic review and resulting restructuring of the SCI Research Programs, and 14) management of an 89% increase (170 to 321) in staff positions. SCI-A supports the SCI’s research spectrum of basic, clinical, translational, and population science and serves 300 members, 7 SCI Research Programs, and 11 SCI Shared Resources. In 2020, SCI-A managed over $49M in revenue, up 79% (from $27.5M) this funding period. SCI-A now provides integrated financial and administrative oversight of the CCTO, which facilitated the accrual of 670 patients to interventional treatment trials in 2020 in the midst of the COVID-19 pandemic. Advancing the SCI’s mission through highly effective administrative management, strategic program planning, and centralized customer-focused services, SCI-A supports the SCI’s Director, D...